In mice, FAK activation in podocytes occurs specifically where laminin 211 is being deposited, propagating disease progression.[24] It is conceivable that therapeutics that either inhibit FAK[24] or abate laminin 211 deposition could be developed for treatment of Alport syndrome. The gene discussed is PTK2; the disease is Alport syndrome.